Compounds and compositions for modulating EGFR mutant kinase activities
USRE50528E1 · kind E1 · reissue
Assignee
Inventors
Key dates
| Filing date | Nov 18, 2022 |
| Grant date | Aug 12, 2025 |
| Priority date | — |
| Expiry date | Nov 18, 2042 |
Classification
- Technology area (CPC —)General
Abstract
The present invention provides a new group of protein kinase inhibitors, aminopyrimidine derivatives, and pharmaceutically acceptable salts thereof that are useful for treating cell proliferative disease and disorder such as cancer and immune disease. The present invention provides methods for synthesizing and administering the protein kinase inhibitor compounds. The present invention also provides pharmaceutical formulations comprising at least one of the protein kinase inhibitor compounds together with a pharmaceutically acceptable carrier, diluent or excipient therefore. The invention also provides useful intermediates generated during the syntheses of the aminopyrimidine derivatives.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.